research

Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases Transcript

Seeking Alpha

2 min read

0 likes

⚡ Quantum Brief

Cue Biopharma presented its R&D progress on CUE-401, a novel therapy targeting autoimmune and inflammatory diseases, during a virtual event on April 7, 2026. The company highlighted its lead asset’s potential to modulate T regulatory cells. Interim CEO Lucinda Warren and Chief Development Officer Daniel Baker led discussions, joined by immunology experts Dr. Richard DiPaolo and Dr. Jonathan Kay. The focus was on CUE-401’s mechanism, which aims to restore immune balance. The presentation emphasized preclinical data suggesting CUE-401’s efficacy in suppressing pro-inflammatory cytokines while promoting regulatory T cell function. This dual approach could address conditions like rheumatoid arthritis and lupus. Cue Biopharma cautioned that forward-looking statements involve risks, citing SEC filings for uncertainties. No updates were provided on clinical trial timelines or regulatory submissions. The event’s recording will be available on the company’s website for 30 days, offering stakeholders access to detailed insights on CUE-401’s development strategy.

AI Audio Summary

0:00 / 0:00

Click to play

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

SA Transcripts159.23K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases April 7, 2026 10:00 AM EDT Company Participants Lucinda Warren - Interim CEO, Interim President,Principal Fin & Accounting Off., Chief Financial & Business Off.Daniel Baker - Interim Chief Development OfficerNatasha Girgis Conference Call Participants Richard DiPaoloJonathan Kay Presentation Operator Good morning, and welcome to the Cue Biopharma Virtual R&D Day. [Operator Instructions] Today's call will focus on a review of Cue Biopharma's lead asset, CUE-401 in development for the treatment of autoimmune and inflammatory diseases. Joining me on today's call is Cue Biopharma's Interim President and Chief Executive Officer, Lucinda Warren; Chief Development Officer, Dr. Daniel Baker; two recognized researchers in T regulatory cells and cytokines, Dr. Richard DiPaolo and Dr. Jonathan Kay, and other members of Cue's management team. Please note that this presentation and discussion is being recorded and will be available under the Events in the News and Publications section of the company's website at cuebiopharma.com. The webcast will be archived for the next 30 days. Additionally, some of the statements we make on this call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those stated or implied by these forward-looking statements due to important risks and uncertainties associated with the company's business, including those set forth in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations section of Cue Biopharma's annual report on Form 10-K for the year ended on December 31, 2025, filed on March 16, 2026, and any other filings that we may make with the SEC. In addition, any forward-looking statements represent our views as of today, April 7, 2026. Cue undertakes no obligation to revise or update any

Read Original

Source Information

Source: Seeking Alpha

Website: https://seekingalpha.com/feed.xml

Discussion

0 professional contributions

Be the first to add a constructive contribution.